



1636
DFV

PATENT
ATTORNEY DOCKET NO. 00786/351005

Certificate of Mailing: Date of Deposit: November 22, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Janet D'Annunzio-Ellis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gary Ruvkun et al.	Art Unit:	1636
Serial No.:	09/844,353	Examiner:	S. Kaushal
Filed:	April 27, 2001	Customer No.:	21559
Title:	THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after the mailing of a first Office Action on the merits, but before the mailing of a final Office Action or a Notice of Allowance. I, the undersigned, hereby certify that each item of information contained in this statement was first cited in a search report from a corresponding international application, dated November 2, 2004, which is not more than three months prior to the filing of this statement.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 22 November 2004



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 00786/351005		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Serial No.		09/844,353		
		Applicant		Gary Ruvkun et al.		
		Filing Date		April 27, 2001		
		Group		1636		
		IDS Filed		November 22, 2004		
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Stern et al., "The Human GRB2 and <i>Drosophila Drk</i> Genes Can Functionally Replace the <i>Caenorhabditis elegans</i> Cell Signaling Gene <i>sem-5</i> ," <i>Mol. Biol. Cell</i> 4(11):1175-1188 (1993).					
	Levitan et al., "Assessment of Normal and Mutant Human Presenilin Function in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 93:14940-14944 (1996).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						